Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astra Joint Venture Keeps Paying Dividends For Merck; “True Up” Due In 2008

Executive Summary

AstraZeneca is still estimating that its final payment in the break-up of the Merck joint venture will be $4.7 bil. in 2008

You may also be interested in...



AstraZeneca’s Gut Instinct: CEO-Designate Is Nexium Brand Builder Brennan

AstraZeneca is elevating an executive integral to the commercial success of the company's proton pump inhibitor franchise with the appointment of U.S. head David Brennan as CEO

AstraZeneca’s Gut Instinct: CEO-Designate Is Nexium Brand Builder Brennan

AstraZeneca is elevating an executive integral to the commercial success of the company's proton pump inhibitor franchise with the appointment of U.S. head David Brennan as CEO

Nexium Discounts Still Capturing “Value” For Brand, AstraZeneca Says

AstraZeneca's Nexium continues to gain share in the proton pump inhibitor category at prices that reflect the "value" of the brand, the company said during an April 29 earnings call

Related Content

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel